AbbVie will present 19 abstracts during the 2019 American Academy of Dermatology (AAD) Annual Meeting, March 1-5, in Washington, D.C., U.S., including new data from the psoriasis pivotal trials for risankizumab, an investigational interleukin-23 (IL-23) inhibitor.
Investigators will highlight risankizumab response over time across various psoriasis patient subgroups in the first integrated efficacy analyses of ultIMMa-1 and ultIMMa-2, two replicate trials comparing risankizumab to STELARA® (ustekinumab) or placebo.
Additionally, AbbVie will present up to 40 months of safety data for risankizumab, as well as longer-term data from IMMvent, a trial exploring the efficacy of switching to risankizumab versus continued HUMIRA use in moderate to severe psoriasis patients with varying levels of intermediate response to HUMIRA after 16 weeks.
AbbVie will also share results from a Phase 2b trial evaluating upadacitinib, an investigational oral JAK1-selective inhibitor, in patients with moderate to severe atopic dermatitis. Additional presentations on HUMIRA will validate hidradenitis suppurativa patient-reported outcome measures, assess its efficacy in nail psoriasis among patients with and without psoriatic disease and highlight nine-year registry data evaluating its long-term safety and efficacy in patients with psoriasis.
Dr Marek Honczarenko, Ph.D., vice president, global immunology development, AbbVie, said: “The breadth of research we are presenting underscores AbbVie’s continued efforts to advance the standard of care and improve treatment expectations for patients living with chronic dermatologic conditions, many of whom still struggle to achieve and maintain their desired treatment goals.”
Risankizumab and upadacitinib are not approved, and their safety and efficacy have not been established by regulatory authorities.